![]() ![]() The fasting blood glucose level and the time from symptom onset to wire crossing were independent predictors of the no-reflow phenomenon (OR, 1.225 95% CI, 1.105 to 2.854 P<0.001) and (OR, 1.049 95% CI, 1.026 to 1.073 P<0.001). The patients with no-reflow had a higher prevalence of MS, a higher level of triglycerides, a lower level of high-density lipoprotein, and a higher fasting blood glucose level. Results: Totally, 26 patients (26%) developed no-reflow. ![]() The MS score was defined as the number of MS components present. MS was defined based on the National Cholesterol Education Program criteria. Angiographic no-reflow was defined as a thrombolysis in myocardial infarction (TIMI) risk score of below 3 or a TIMI risk score of 3 with a myocardial blushing grade (MBG) of 0 to 1 in the absence of mechanical complications. Methods: We prospectively included 100 patients with STEMI treated with PPCI. We aimed to examine the association between angiographic outcomes including angiographic no-reflow and MS. Background: The relationship between metabolic syndrome (MS) and the MS score and the angiographic outcome of primary percutaneous coronary intervention (PPCI) for ST-segment-elevation myocardial infarction (STEMI) is still unclear. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |